A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
This is a randomized, multicentre, open-label, Phase 2 study of the SINE Selinexor given
orally versus specified investigator choices (one of three potential salvage therapies).
Patients age ≥ 60 years with relapsed/refractory AML of any type except for AML M3, after
one prior therapy only, who have never undergone and who are not currently eligible for stem
cell transplantation and are currently deemed unfit for intensive chemotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society